Material Weakness (worsened) — IT control deficiency scope expanded from enterprise resource planning system to entire information technology environment; material weakness persists into 2025 with remediation timeline extended.
Voluntary Recall (new) — Asteria Health initiated voluntary recall of hormone pellets shipped May 2025–January 2026 due to potential metal particulate matter; $1.3M impairment charge recorded Q4 2025 with additional future costs expected.

NASDAQ: BTMD biote Corp. 10-K

Biote revenue slips 2.5% as practitioner retention falls; $18.5M Donovitz settlement closes litigation

Filed March 13, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 14, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade BTMD commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 5, 2026 12:21 AM